Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

使用表观遗传调节剂使肿瘤细胞对癌症药物重新敏感

卷 21, 期 4, 2021

发表于: 07 January, 2021

页: [353 - 359] 页: 7

弟呕挨: 10.2174/1568009620666210108102723

open access plus

摘要

癌症耐药性是癌症治疗的主要问题。 虽然许多药物在一线治疗中可能有效，但癌细胞可能由于遗传（突变和染色体畸变）以及表观遗传变化而产生耐药性。 因此，许多研究致力于表观遗传药物在不同肿瘤实体中规避对传统疗法的耐药性和提高免疫检查点疗法的效率。 此外，将已经批准的药物与表观遗传修饰剂结合重新定位可以增强其疗效，因此可能是一种有吸引力的癌症治疗策略。 总之，我们概括了表观遗传药物及其在调节对常规和免疫疗法的敏感性方面的目标的当前数据，提供证据表明表观遗传修饰剂改变表达谱具有改善癌症患者临床结果的巨大潜力。

关键词: 癌症耐药性、表观遗传药物、DNA 甲基化、组蛋白修饰、再敏化、组合治疗。

« Previous Next »
图形摘要

[1]
Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis, 2010, 31(1), 27-36.
[http://dx.doi.org/10.1093/carcin/bgp220] [PMID: 19752007]
[2]
Putiri, E.L.; Robertson, K.D. Epigenetic mechanisms and genome stability. Clin. Epigenetics, 2011, 2(2), 299-314.
[http://dx.doi.org/10.1007/s13148-010-0017-z] [PMID: 21927626]
[3]
Ducasse, M.; Brown, M.A. Epigenetic aberrations and cancer. Mol. Cancer, 2006, 5, 60.
[http://dx.doi.org/10.1186/1476-4598-5-60] [PMID: 17092350]
[4]
Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 2002, 21(35), 5427-5440.
[http://dx.doi.org/10.1038/sj.onc.1205600] [PMID: 12154405]
[5]
Estécio, M.R.; Issa, J.P. Dissecting DNA hypermethylation in cancer. FEBS Lett., 2011, 585(13), 2078-2086.
[http://dx.doi.org/10.1016/j.febslet.2010.12.001] [PMID: 21146531]
[6]
Yang, X.; Han, H.; De Carvalho, D.D.; Lay, F.D.; Jones, P.A.; Liang, G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell, 2014, 26(4), 577-590.
[http://dx.doi.org/10.1016/j.ccr.2014.07.028] [PMID: 25263941]
[7]
Lu, Y.; Chan, Y.T.; Tan, H.Y.; Li, S.; Wang, N.; Feng, Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol. Cancer, 2020, 19(1), 79.
[http://dx.doi.org/10.1186/s12943-020-01197-3] [PMID: 32340605]
[8]
Jones, P.A. The DNA methylation paradox. Trends Genet., 1999, 15(1), 34-37.
[http://dx.doi.org/10.1016/S0168-9525(98)01636-9] [PMID: 10087932]
[9]
Wolff, F.; Leisch, M.; Greil, R.; Risch, A.; Pleyer, L. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun. Signal., 2017, 15(1), 13.
[http://dx.doi.org/10.1186/s12964-017-0168-z] [PMID: 28359286]
[10]
Pleyer, L.; Greil, R. Digging deep into “dirty” drugs - modulation of the methylation machinery. Drug Metab. Rev., 2015, 47(2), 252-279.
[http://dx.doi.org/10.3109/03602532.2014.995379] [PMID: 25566693]
[11]
Van, H.T.; Santos, M.A. Histone modifications and the DNA double-strand break response. Cell Cycle, 2018, 17(21-22), 2399-2410.
[http://dx.doi.org/10.1080/15384101.2018.1542899] [PMID: 30394812]
[12]
Audia, J.E.; Campbell, R.M. Histone Modifications and Cancer. Cold Spring Harb. Perspect. Biol., 2016, 8(4), a019521.
[http://dx.doi.org/10.1101/cshperspect.a019521] [PMID: 27037415]
[13]
Jones, P.A.; Issa, J.P.; Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet., 2016, 17(10), 630-641.
[http://dx.doi.org/10.1038/nrg.2016.93] [PMID: 27629931]
[14]
Eckschlager, T.; Plch, J.; Stiborova, M.; Hrabeta, J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 2017, 18(7), E1414.
[http://dx.doi.org/10.3390/ijms18071414] [PMID: 28671573]
[15]
Silverman, L.R.; Demakos, E.P.; Peterson, B.L.; Kornblith, A.B.; Holland, J.C.; Odchimar-Reissig, R.; Stone, R.M.; Nelson, D.; Powell, B.L.; DeCastro, C.M.; Ellerton, J.; Larson, R.A.; Schiffer, C.A.; Holland, J.F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol., 2002, 20(10), 2429-2440.
[http://dx.doi.org/10.1200/JCO.2002.04.117] [PMID: 12011120]
[16]
Pleyer, L.; Burgstaller, S.; Stauder, R.; Girschikofsky, M.; Sill, H.; Schlick, K.; Thaler, J.; Halter, B.; Machherndl-Spandl, S.; Zebisch, A.; Pichler, A.; Pfeilstöcker, M.; Autzinger, E.M.; Lang, A.; Geissler, K.; Voskova, D.; Geissler, D.; Sperr, W.R.; Hojas, S.; Rogulj, I.M.; Andel, J.; Greil, R. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J. Hematol. Oncol., 2016, 9, 39.
[http://dx.doi.org/10.1186/s13045-016-0263-4] [PMID: 27084507]
[17]
Kantarjian, H.; Issa, J.P.; Rosenfeld, C.S.; Bennett, J.M.; Albitar, M.; DiPersio, J.; Klimek, V.; Slack, J.; de Castro, C.; Ravandi, F.; Helmer, R., III; Shen, L.; Nimer, S.D.; Leavitt, R.; Raza, A.; Saba, H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 2006, 106(8), 1794-1803.
[http://dx.doi.org/10.1002/cncr.21792] [PMID: 16532500]
[18]
McDermott, J.; Jimeno, A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc), 2014, 50(5), 337-345.
[http://dx.doi.org/10.1358/dot.2014.50.5.2138703] [PMID: 24918834]
[19]
Richardson, P.G.; Laubach, J.P.; Lonial, S.; Moreau, P.; Yoon, S.S.; Hungria, V.T.; Dimopoulos, M.A.; Beksac, M.; Alsina, M.; San-Miguel, J.F. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev. Anticancer Ther., 2015, 15(7), 737-748.
[http://dx.doi.org/10.1586/14737140.2015.1047770] [PMID: 26051506]
[20]
Frye, R.; Myers, M.; Axelrod, K.C.; Ness, E.A.; Piekarz, R.L.; Bates, S.E.; Booher, S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin. J. Oncol. Nurs., 2012, 16(2), 195-204.
[http://dx.doi.org/10.1188/12.CJON.195-204] [PMID: 22459529]
[21]
Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 2007, 12(10), 1247-1252.
[http://dx.doi.org/10.1634/theoncologist.12-10-1247] [PMID: 17962618]
[22]
Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target. Ther., 2019, 4, 62.
[http://dx.doi.org/10.1038/s41392-019-0095-0] [PMID: 31871779]
[23]
Cuyàs, E.; Gumuzio, J.; Verdura, S.; Brunet, J.; Bosch-Barrera, J.; Martin-Castillo, B.; Alarcón, T.; Encinar, J.A.; Martin, Á.G.; Menendez, J.A. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging (Albany NY), 2020, 12(6), 4794-4814.
[http://dx.doi.org/10.18632/aging.102887] [PMID: 32191225]
[24]
Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4), 663-676.
[http://dx.doi.org/10.1016/j.cell.2006.07.024] [PMID: 16904174]
[25]
Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131(5), 861-872.
[http://dx.doi.org/10.1016/j.cell.2007.11.019] [PMID: 18035408]
[26]
Takeda, K.; Mizushima, T.; Yokoyama, Y.; Hirose, H.; Wu, X.; Qian, Y.; Ikehata, K.; Miyoshi, N.; Takahashi, H.; Haraguchi, N.; Hata, T.; Matsuda, C.; Doki, Y.; Mori, M.; Yamamoto, H. Sox2 is associated with cancer stem-like properties in colorectal cancer. Sci. Rep., 2018, 8(1), 17639.
[http://dx.doi.org/10.1038/s41598-018-36251-0] [PMID: 30518951]
[27]
Ravindran Menon, D.; Luo, Y.; Arcaroli, J.J.; Liu, S.; KrishnanKutty, L.N.; Osborne, D.G.; Li, Y.; Samson, J.M.; Bagby, S.; Tan, A.C.; Robinson, W.A.; Messersmith, W.A.; Fujita, M. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res., 2018, 78(23), 6561-6574.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-0330] [PMID: 30297536]
[28]
Chen, Y.; Jie, W.; Yan, W.; Zhou, K.; Xiao, Y. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Crit. Rev. Eukaryot. Gene Expr., 2012, 22(1), 53-59.
[http://dx.doi.org/10.1615/CritRevEukarGeneExpr.v22.i1.40] [PMID: 22339659]
[29]
Zhang, X.; Lu, F.; Wang, J.; Yin, F.; Xu, Z.; Qi, D.; Wu, X.; Cao, Y.; Liang, W.; Liu, Y.; Sun, H.; Ye, T.; Zhang, H. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep., 2013, 5(2), 445-457.
[http://dx.doi.org/10.1016/j.celrep.2013.09.018] [PMID: 24139802]
[30]
Benedetti, R.; Dell’Aversana, C.; De Marchi, T.; Rotili, D.; Liu, N.Q.; Novakovic, B.; Boccella, S.; Di Maro, S.; Cosconati, S.; Baldi, A.; Niméus, E.; Schultz, J.; Höglund, U.; Maione, S.; Papulino, C.; Chianese, U.; Iovino, F.; Federico, A.; Mai, A.; Stunnenberg, H.G.; Nebbioso, A.; Altucci, L. Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers (Basel), 2019, 11(12), E2027.
[http://dx.doi.org/10.3390/cancers11122027] [PMID: 31888209]
[31]
Reinert, T.; Saad, E.D.; Barrios, C.H.; Bines, J. Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front. Oncol., 2017, 7, 26.
[http://dx.doi.org/10.3389/fonc.2017.00026] [PMID: 28361033]
[32]
Siefker-Radtke, A.O. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Expert Rev. Anticancer Ther., 2009, 9(12), 1701-1703.
[http://dx.doi.org/10.1586/era.09.146] [PMID: 19954279]
[33]
Ryu, H.; Jin, H.; Ho, J.N.; Bae, J.; Lee, E.; Lee, S.E.; Lee, S. Suberoylanilide hydroxamic acid can re-sensitize a cisplatin-resistant human bladder cancer. Biol. Pharm. Bull., 2019, 42(1), 66-72.
[http://dx.doi.org/10.1248/bpb.b18-00545] [PMID: 30606990]
[34]
Komatsu, S.; Moriya, S.; Che, X.F.; Yokoyama, T.; Kohno, N.; Miyazawa, K. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem. Biophys. Res. Commun., 2013, 437(1), 41-47.
[http://dx.doi.org/10.1016/j.bbrc.2013.06.032] [PMID: 23792097]
[35]
Jin, K.L.; Park, J.Y.; Noh, E.J.; Hoe, K.L.; Lee, J.H.; Kim, J.H.; Nam, J.H. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J. Gynecol. Oncol., 2010, 21(4), 262-268.
[http://dx.doi.org/10.3802/jgo.2010.21.4.262] [PMID: 21278889]
[36]
Warrener, R.; Beamish, H.; Burgess, A.; Waterhouse, N.J.; Giles, N.; Fairlie, D.; Gabrielli, B. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J., 2003, 17(11), 1550-1552.
[http://dx.doi.org/10.1096/fj.02-1003fje] [PMID: 12824307]
[37]
Fang, F.; Balch, C.; Schilder, J.; Breen, T.; Zhang, S.; Shen, C.; Li, L.; Kulesavage, C.; Snyder, A.J.; Nephew, K.P.; Matei, D.E. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer, 2010, 116(17), 4043-4053.
[http://dx.doi.org/10.1002/cncr.25204] [PMID: 20564122]
[38]
Fang, F.; Munck, J.; Tang, J.; Taverna, P.; Wang, Y.; Miller, D.F.; Pilrose, J.; Choy, G.; Azab, M.; Pawelczak, K.S.; VanderVere- Carozza, P.; Wagner, M.; Lyons, J.; Matei, D.; Turchi, J.J.; Nephew, K.P. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res., 2014, 20(24), 6504-6516.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-1553] [PMID: 25316809]
[39]
Fang, F.; Zuo, Q.; Pilrose, J.; Wang, Y.; Shen, C.; Li, M.; Wulfridge, P.; Matei, D.; Nephew, K.P. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget, 2014, 5(11), 3579-3589.
[http://dx.doi.org/10.18632/oncotarget.1961] [PMID: 25003579]
[40]
Matei, D.; Fang, F.; Shen, C.; Schilder, J.; Arnold, A.; Zeng, Y.; Berry, W.A.; Huang, T.; Nephew, K.P. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res., 2012, 72(9), 2197-2205.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3909] [PMID: 22549947]
[41]
Jiang, Z.; Li, W.; Hu, X.; Zhang, Q.; Sun, T.; Cui, S.; Wang, S.; Ouyang, Q.; Yin, Y.; Geng, C.; Tong, Z.; Cheng, Y.; Pan, Y.; Sun, Y.; Wang, H.; Ouyang, T.; Gu, K.; Feng, J.; Wang, X.; Wang, S.; Liu, T.; Gao, J.; Cristofanilli, M.; Ning, Z.; Lu, X. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2019, 20(6), 806-815.
[http://dx.doi.org/10.1016/S1470-2045(19)30164-0] [PMID: 31036468]
[42]
Raynal, N.J.; Da Costa, E.M.; Lee, J.T.; Gharibyan, V.; Ahmed, S.; Zhang, H.; Sato, T.; Malouf, G.G.; Issa, J.J. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Mol. Cancer Ther., 2017, 16(2), 397-407.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0588] [PMID: 27980103]
[43]
Si, J.; Boumber, Y.A.; Shu, J.; Qin, T.; Ahmed, S.; He, R.; Jelinek, J.; Issa, J.P. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res., 2010, 70(17), 6968-6977.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-4474] [PMID: 20713525]
[44]
Raynal, N.J.; Si, J.; Taby, R.F.; Gharibyan, V.; Ahmed, S.; Jelinek, J.; Estécio, M.R.; Issa, J.P. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res., 2012, 72(5), 1170-1181.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3248] [PMID: 22219169]
[45]
Renaud, S.; Loukinov, D.; Abdullaev, Z.; Guilleret, I.; Bosman, F.T.; Lobanenkov, V.; Benhattar, J. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res., 2007, 35(4), 1245-1256.
[http://dx.doi.org/10.1093/nar/gkl1125] [PMID: 17267411]
[46]
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[47]
Pestana, A.; Vinagre, J.; Sobrinho-Simões, M.; Soares, P. TERT biology and function in cancer: beyond immortalisation. J. Mol. Endocrinol., 2017, 58(2), R129-R146.
[http://dx.doi.org/10.1530/JME-16-0195] [PMID: 28057768]
[48]
Devereux, T.R.; Horikawa, I.; Anna, C.H.; Annab, L.A.; Afshari, C.A.; Barrett, J.C. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res., 1999, 59(24), 6087-6090.
[PMID: 10626795]
[49]
Guilleret, I.; Benhattar, J. Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem. Biophys. Res. Commun., 2004, 325(3), 1037-1043.
[http://dx.doi.org/10.1016/j.bbrc.2004.10.137] [PMID: 15541393]
[50]
Guilleret, I.; Yan, P.; Grange, F.; Braunschweig, R.; Bosman, F.T.; Benhattar, J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer, 2002, 101(4), 335-341.
[http://dx.doi.org/10.1002/ijc.10593] [PMID: 12209957]
[51]
Renaud, S.; Loukinov, D.; Bosman, F.T.; Lobanenkov, V.; Benhattar, J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res., 2005, 33(21), 6850-6860.
[http://dx.doi.org/10.1093/nar/gki989] [PMID: 16326864]
[52]
Dessain, S.K.; Yu, H.; Reddel, R.R.; Beijersbergen, R.L.; Weinberg, R.A. Methylation of the human telomerase gene CpG island. Cancer Res., 2000, 60(3), 537-541.
[PMID: 10676632]
[53]
Guilleret, I.; Benhattar, J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp. Cell Res., 2003, 289(2), 326-334.
[http://dx.doi.org/10.1016/S0014-4827(03)00281-7] [PMID: 14499633]
[54]
Kitagawa, Y.; Kyo, S.; Takakura, M.; Kanaya, T.; Koshida, K.; Namiki, M.; Inoue, M. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin. Cancer Res., 2000, 6(7), 2868-2875.
[PMID: 10914736]
[55]
Kumakura, S.; Tsutsui, T.W.; Yagisawa, J.; Barrett, J.C.; Tsutsui, T. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res., 2005, 65(7), 2778-2786.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-1819] [PMID: 15805278]
[56]
Azouz, A.; Wu, Y.L.; Hillion, J.; Tarkanyi, I.; Karniguian, A.; Aradi, J.; Lanotte, M.; Chen, G.Q.; Chehna, M.; Ségal-Bendirdjian, E. Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia, 2010, 24(3), 613-622.
[http://dx.doi.org/10.1038/leu.2009.283] [PMID: 20072159]
[57]
Losi, L.; Lauriola, A.; Tazzioli, E.; Gozzi, G.; Scurani, L.; D’Arca, D.; Benhattar, J. Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines. J. Ovarian Res., 2019, 12(1), 62.
[http://dx.doi.org/10.1186/s13048-019-0536-y] [PMID: 31291979]
[58]
Darvin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med., 2018, 50(12), 1-11.
[http://dx.doi.org/10.1038/s12276-018-0191-1] [PMID: 30546008]
[59]
Sasidharan Nair, V.; El Salhat, H.; Taha, R.Z.; John, A.; Ali, B.R.; Elkord, E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin. Epigenetics, 2018, 10, 78.
[http://dx.doi.org/10.1186/s13148-018-0512-1] [PMID: 29983831]
[60]
Ghoneim, H.E. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell, 2017, 170(1), 142-157.
[61]
Luo, N.; Nixon, M.J.; Gonzalez-Ericsson, P.I.; Sanchez, V.; Opalenik, S.R.; Li, H.; Zahnow, C.A.; Nickels, M.L.; Liu, F.; Tantawy, M.N.; Sanders, M.E.; Manning, H.C.; Balko, J.M. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat. Commun., 2018, 9(1), 248.
[http://dx.doi.org/10.1038/s41467-017-02630-w] [PMID: 29339738]
[62]
Marwitz, S.; Scheufele, S.; Perner, S.; Reck, M.; Ammerpohl, O.; Goldmann, T. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression. Clin. Epigenetics, 2017, 9, 51.
[http://dx.doi.org/10.1186/s13148-017-0354-2] [PMID: 28503213]
[63]
Yang, H.; Bueso-Ramos, C.; DiNardo, C.; Estecio, M.R.; Davanlou, M.; Geng, Q.R.; Fang, Z.; Nguyen, M.; Pierce, S.; Wei, Y.; Parmar, S.; Cortes, J.; Kantarjian, H.; Garcia-Manero, G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia, 2014, 28(6), 1280-1288.
[http://dx.doi.org/10.1038/leu.2013.355] [PMID: 24270737]
[64]
Ørskov, A.D.; Treppendahl, M.B.; Skovbo, A.; Holm, M.S.; Friis, L.S.; Hokland, M.; Grønbæk, K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget, 2015, 6(11), 9612-9626.
[http://dx.doi.org/10.18632/oncotarget.3324] [PMID: 25823822]
[65]
Bally, A.P.; Austin, J.W.; Boss, J.M. Genetic and epigenetic regulation of PD-1 expression. J. Immunol., 2016, 196(6), 2431-2437.
[http://dx.doi.org/10.4049/jimmunol.1502643] [PMID: 26945088]
[66]
Goltz, D.; Gevensleben, H.; Vogt, T.J.; Dietrich, J.; Golletz, C.; Bootz, F.; Kristiansen, G.; Landsberg, J.; Dietrich, D. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight, 2018, 3(13), 96793.
[http://dx.doi.org/10.1172/jci.insight.96793] [PMID: 29997292]
[67]
Sun, F.; Li, L.; Yan, P.; Zhou, J.; Shapiro, S.D.; Xiao, G.; Qu, Z. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance. Nat. Commun., 2019, 10(1), 5324.
[http://dx.doi.org/10.1038/s41467-019-13331-x] [PMID: 31757943]
[68]
Qu, Z.; Fu, J.; Yan, P.; Hu, J.; Cheng, S.Y.; Xiao, G. Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer. J. Biol. Chem., 2010, 285(16), 11786-11792.
[http://dx.doi.org/10.1074/jbc.M109.086561] [PMID: 20185823]
[69]
Qu, Z.; Yan, P.; Fu, J.; Jiang, J.; Grusby, M.J.; Smithgall, T.E.; Xiao, G. DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target. Cancer Res., 2010, 70(5), 1766-1772.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3263] [PMID: 20145149]
[70]
Sun, F.; Xiao, Y.; Qu, Z. Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to persistently activate nuclear factor κB (NF-κB) and STAT3 transcription factors for tumorigenesis and tumor maintenance. J. Biol. Chem., 2015, 290(12), 7362-7368.
[http://dx.doi.org/10.1074/jbc.C115.637918] [PMID: 25681443]
[71]
Yan, P.; Fu, J.; Qu, Z.; Li, S.; Tanaka, T.; Grusby, M.J.; Xiao, G. PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood, 2009, 113(18), 4370-4380.
[http://dx.doi.org/10.1182/blood-2008-10-185660] [PMID: 19131544]

Rights & Permissions Print Cite
Article Metrics
80
© 2024 Bentham Science Publishers | Privacy Policy